- \n
- Involving over 350
\nfacilities, DHL distributed more than 200 million vaccine doses to over 120
\ncountries to date<\/b><\/li>\n- From
\n2022 onward, a further <\/b>7-9 billion doses of
\nvaccines are necessary annually to keep (re-)infection rates low and slow down
\nthe pace of virus mutations<\/b><\/li>\n- Locally adapted
\nlast-mile delivery, distribution models and a constant stock of vaccines will
\ncontinue to be critical beyond 2021<\/b><\/li>\n<\/ul>\nBONN, GERMANY –\u00a0Media OutReach<\/a>\u00a0– 18 May 2021 – <\/b>It has been more than a year since the world woke up
\nto the news of the new SARS-COV-2 virus. What followed was the largest global
\nhealth crisis in 100 years. The disruptions to every aspect of society have
\nbeen profound. Logistics and supply chain management have played a vital role
\nin pandemic management right from the start to ensure the availability and
\ndistribution of key pandemic management tools: medicines and medical supplies,
\nsuch as vaccines, test kits, ancillary supplies, treatments, and personal
\nprotective equipment (PPE). With over 200 million doses of all approved
\nvaccines distributed to over 120 countries and 9,000 operated flights in which
\nmore than 350 DHL facilities were involved, DHL was part of the response
\nstrategy from the beginning. Over 50 bilateral and multilateral collaborations
\nwith partners in both the pharma and public sector and several new dedicated
\nservices were created to stem this task. The recently published DHL white paper
\non “Revisiting Pandemic Resilience” takes one step back and sheds light into
\nwhat the sector has learned from the race against COVID-19 to be best prepared
\nto handle public health emergencies in the future.<\/p>\n
\n <\/p>\n“Logistics and supply chain management play a key role
\nin pandemic management. Keeping supply chains running and ensuring delivery for
\nessential health supplies provided valuable lessons”, explains Katja Busch,
\nChief Commercial Officer DHL. “We rolled out new dedicated services for the
\nvaccine distribution at unprecedented speed. All sectors, industries, and
\nnations must work together to successfully end the acute phase of this
\npandemic. Forming strong partnerships and leveraging data analytics will be key.
\nWe also need to remain prepared for high patient and vaccine volumes, maintain
\nlogistics infrastructure and capacity, while planning for seasonal fluctuations
\nby providing a stable and well-equipped platform for the years to come.”<\/p>\n
\n <\/p>\nThere are important achievements across research and
\ndevelopment, production, and supply chain management as well as policy that
\nwill help us get through the crisis as a global community. The foundation of
\nthis was laid by research and development by developing a vaccine five times
\nfaster than any other vaccine in history and ramping up production in record
\ntime \u2013 quadrupling pre-COVID vaccine production capacities. Together with
\nlogistics and supply chain, they were able to get the life-saving vaccines to
\npatients worldwide. Although unprecedented cold chain requirements of up to -70\u00b0C had to be met,
\nlogistics were able to roll out the distribution three times faster than usual.
\nFurthermore, multilateral action by public health and policy actors has
\nprovided a conducive framework for rapid vaccine development and deployment.<\/p>\n
\n <\/p>\n“We are proud and privileged to have been involved in the
\nshipments of vaccines, including to Singapore<\/a>,\u00a0Malaysia<\/a>,\u00a0Japan<\/a>,\u00a0Australia<\/a>
\nand\u00a0New
\nZealand<\/a>. Our trained specialists have ensured that the stringent
\nrequirements were strictly adhered to and everything proceeded as planned. We
\nbelieve that it is important for the logistics community to continue to play
\nour part and equally advocate for constructive collaborations to boost our
\nefforts in the fight against the pandemic,” said Leonora Lim, Head of Life
\nScience and Healthcare, DHL Customer Solutions and Innovation, Asia Pacific.<\/p>\n
\n <\/p>\nCollaboration key to global vaccine distribution<\/b><\/p>\n
\n <\/p>\nFor high levels of
\nimmunization, around 10 billion vaccine doses are required globally by end of
\n2021. However, only four countries have achieved vaccination rates >50% to
\ndate and many of the remaining countries and territories have less-developed
\ninfrastructure, making the rollout more difficult. To speed up vaccine
\ndistribution, the following areas need to be looked at:<\/p>\n- \n
- Industries and
\nnations must foster collaboration<\/b>, paying special attention to building
\nstrong partnerships and a supportive data backbone. <\/li>\n- For
\nsafe inbound supply flows<\/b>, proactive
\ntransport-capacity management and sustainable return flows for packaging are
\nneeded. This is particularly critical as more than 95% of global COVID-19
\nvaccine doses are produced in just eight countries and need to be delivered
\nworldwide. <\/li>\n- Also
\nlocally tailored last-mile, ground
\ndistribution models<\/b> should be put into place with a focus on strategic
\nlocation of warehouses, the synchronization of vaccines and ancillaries flow as
\nwell as the number and location of vaccination points.<\/li>\n<\/ul>\nThe set-up logistics
\ninfrastructure and capacity should be kept on that level as in the coming years
\nfurther 7-9 billion doses of vaccines are necessary annually to keep
\n(re-)infection rates low and slow down the pace of virus mutations \u2013 seasonal
\nfluctuations not counted.<\/p>\n
\n <\/p>\nPlanning for the future <\/b><\/p>\n
\n <\/p>\nPlanning for the
\nfuture it is essential to identify and prevent health crises early through
\nactive partnerships, expanded global warning systems, an integrated epidemic-preventions
\nagenda and targeted R&D investments. It is also recommended to expand and
\ninstitutionalize virus containment and countermeasures (e. g. digital contact
\ntracing and national stockpiles) to ensure strategic preparedness and more
\nefficient response times. To facilitate a speedy rollout of medication (i. e.
\ndiagnostics, therapeutics and vaccines), governments and industries should
\nemploy “ever-warm” manufacturing capacity, blueprint research, production, and
\nprocurement plans, as well as expand local deployment capabilities.<\/p>\n
\n <\/p>\n\u00a0<\/p>\n
\n <\/p>\nTo read the complete white paper, please click on the following link:
https:\/\/www.dhl.com\/pandemic-resilience<\/a> <\/p>\n
\n <\/p>\nNote to editors:<\/span><\/p>\n
\n <\/p>\nAs the leading logistics
\nprovider for the life sciences and healthcare industry, DHL provides
\nforward-thinking, intelligent healthcare logistics through a holistic range of
\npatient-centric solutions. More than 9,000 specialists work across DHL’s
\ndedicated global network so that pharmaceutical, medical devices, clinical
\ntrials and research organizations, wholesalers and distributors, as well as
\nhospitals and healthcare providers are connected across the value chain and
\nthrough digitalization, from clinical trials to point of care, and every step
\nin between.<\/span><\/p>\n
\n <\/p>\nThe organization
\nprovides high-quality, fully compliant logistics and supply chain services, and
\nchampions innovative technologies that benefit customers and deliver better
\ncare for patients. DHL’s portfolio for the healthcare industry includes 150+
\npharmacists, 20+ clinical trials depots, 100+ certified stations, 160+
\nGDP-qualified warehouses, 15+ GMP-certified sites, 135+ medical express sites,
\nand a time-definite international express network covering 220 countries and
\nterritories.<\/span><\/p>\n
\n <\/p>\n\u00a0<\/span><\/p>\n
\n <\/p>\nYou can find the press release for download
\nas well as further information on dpdhl.com\/pressreleases<\/a><\/p>\n
\n <\/p>\n\u00a0<\/p>\n
\n <\/p>\nOn
\nthe Internet: dpdhl.com\/press<\/a><\/p>\n
\n <\/p>\nFollow
\nus at:![](\"https:\/\/www.media-outreach.com\/Release\/templates\/images\/socialMedia\/iconmonstr-twitter-1-24.png\"\/)
twitter.com\/DeutschePostDHL<\/a><\/p>\n<\/p><\/div>\n - For
- From